Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Crispr Therapeutics AG (CRSP) stock saw a modest uptick, ending the day at $40.49 which represents a slight increase of $0.49 or 1.23% from the prior close of $40. The stock opened at $40 and touched ...
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.
In the latest trading session, Cathie Wood's ARK ETFs continued to adjust their portfolios, with significant moves seen in both buying and selling across various sectors. The largest transaction for ...
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type a few symbols and Take a Trial. The signals for these will appear ...
KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...
CRISPR Therapeutics AG (NASDAQ:CRSP) has reported that its CEO, Samarth Kulkarni, sold a total of $1,449,628 worth of company stock, according to a recent SEC filing. The... ZUG, Switzerland ...
CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...